Table 2 Description of animals bearing mammary gland tumors. The pathology of mammary tumors and premalignant lesions were assessed according to the consensus report from the Annapolis meeting on the mammary pathology of genetically engineered mice [33]. WT, wild type; T16, MMTV-cortactin mice; MP1, MMTV-cyclin D1 mice; T16*MP1, bitransgenic mice; wk, weeks; pregn, pregnancies; MG, mammary gland; d, diameter; cm, centimeter; HAN, hyperplastic alveolar nodules; MIN, mammary intraepithelial neoplasia; hyp, hypofyse enlargement (+); carc, carcinoma; IHC-, cortactin immunohistochemical staining negative; Y, yes; N, no; nd, not done.
Animal | Age (wk) | No. of pregn | MG tumor | Size (d,cm) | No. of HAN | MIN | Lung tumor | Hyp | Metas tasis |
|---|---|---|---|---|---|---|---|---|---|
WT | Â | Â | Â | Â | Â | Â | Â | Â | Â |
N.1 | 103 | 4 | spindle cell | 0.8 | 7 | Y | N | - | Â |
N.2 | 93 | 5 | adenosquamous carc. + transformation to spindle cell | 1.0 | 3 | Y | N | - | Â |
N.3 | 108 | 6 | 2 adenosquamous carc. + 1 cribriform | 1.0 0.4 | 8 | Y | Y, carc. | + | Â |
N.4 | 111 | 4 | adenosquamous carc. | 0.3 | 3 | N | Y | - | Â |
N.5 | 102 | 6 | adeno carc. | 0.8 | 6 | Y | N | - | Â |
N.6 | 127 | 5 | adenosquamous carc. | 0.5 | 8 | Y | N | - | Â |
N.7 | 78 | 7 | adeno carc. | 0.7 | 1 | Y | Y,carc. | - | Â |
N.8 | 118 | 5 | adenosquamous carc. | 0.5 | 10 | Y | Y | - | liver |
N.9 | 91 | 5 | adenosquamous carc. | 0.2 | 2 | Y | Y,carc. | - | Â |
N.10 | 63 | 5 | adeno carc. | 1.0 | 6 | Y | N | - | Â |
N.11 | 102 | 5 | spindle cell | 0.8 | 5 | Y | N | + | Â |
N.12 | 61 | 5 | neuroendocrine carcinoid | 1.0 | 0 | Y | Y | nd | lung |
N.13 | 105 | 4 | adenosquamous carc. | 0.4 | 0 | N | N | nd | Â |
T16 | Â | Â | Â | Â | Â | Â | Â | Â | Â |
N.1 | 90 | 6 | adenosquamous carc. (IHC-) | 1.0 | 4 | Y | N | nd | Â |
N.2 | 120 | 4 | adenosquamous carc. (IHC-) | 0.5 | 5 | Y | N | - | Â |
N.3 | 60 | 2 | part adeno carc. + part spindle cell (IHC-) | 2.0 | 3 | Y | Y | - | lung (?) |
N.4 | 113 | 5 | adenosquamous carc. (IHC-) | 0.8 | 3 | N | N | - | Â |
N.5 | 109 | 5 | adenosquamous carc. | 0.3 | 4 | N | Y | - | Â |
N.6 | 108 | 5 | cribriform + adenosquamous carc.(IHC-) | 1.0 | 7 | Y | N | + | Â |
MP1 | Â | Â | Â | Â | Â | Â | Â | Â | Â |
N.1 | 97 | 5 | 2 adenosquamous carc. | 0.5 | 7 | Y | N | - | Â |
| Â | Â | Â | 1 papillair carc. | 0.5 | Â | Â | Â | Â | Â |
N.2 | 100 | 6 | papillair carc. | 0.4 | 0 | Y | Y | - | Â |
N.3 | 53 | 7 | endocrine carcinoid | 2.0 | 0 | N | N | - | Â |
N.4 | 100 | 4 | adenosquamous carc. | 0.3 | 3 | N | N | - | Â |
N.5 | 98 | 3 | adenosquamous carc. | 2.0 | 0 | Y | Y | - | lung |
N.6 | 101 | 5 | cribriform | 2.0 | 2 | N | Y | - | Â |
T16*MP | Â | Â | Â | Â | Â | Â | Â | Â | Â |
N.1 | 69 | 2 | adeno carc. (IHC-) | 1.5 | 2 | N | N | - | Â |
N.2 | 117 | 7 | adenosquamous carc. (IHC-) | 0.2 | 3 | Y | Y | - | Â |
N.3 | 95 | 3 | adenosquamous carc. (IHC-) | 0.2 | 4 | Y | N | - | Â |
N.4 | 101 | 4 | papillair carc. | 0.8 | 0 | Y | Y,carc | - | Â |
N.5 | 93 | 5 | adenosquamous carc. (IHC-) | 0.2 | 3 | Y | Y,carc | - | Â |
N.6 | 95 | 4 | (adeno)squamous carc. (IHC-) | 1.0 | 4 | N | N | - | Â |
N.7 | 55 | 5 | (adeno)squamous carc. | 1.0 | 0 | Y | N | - | Â |